PFMU
HZNP

Privium Fund Management (UK)’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Privium Fund Management (UK)’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-63,147
Closed -$7.31M – 102
2023
Q3 		$7.31M Buy
63,147
+40,700
+181% +$4.37M 5.72% 4
2023
Q2 		$2.32M Sell
22,447
-23,054
-51% -$2.43M 1.82% 10
2023
Q1 		$4.97M Buy
+45,501
New +$5.03M 3.92% 7

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Privium Fund Management (UK)'s HZNP Position: Q4 2023 in Review

Privium Fund Management (UK) sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 63,147 shares — an estimated $7.31M sold.

Privium Fund Management (UK) first reported a position in HZNP in Q1 2023 and held it in 3 quarters. The position peaked at $7.31M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Privium Fund Management (UK) reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Privium Fund Management (UK) sold 63,147 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $7.31M.
  • Privium Fund Management (UK) first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023 and held it in 3 quarters.
  • Privium Fund Management (UK)'s Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $7.31M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Privium Fund Management (UK)'s 13F filing for Q4 2023, filed 13 Feb 2024.